| 14.2807 -0.279 (-1.92%) | 08-26 11:48 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 23.39 | 1-year : | 28.23 |
| Resists | First : | 20.02 | Second : | 24.17 |
| Pivot price | 15.21  |
|||
| Supports | First : | 13.32 | Second : | 11.09 |
| MAs | MA(5) : | 14.32 |
MA(20) : | 15.72 |
| MA(100) : | 19.18 |
MA(250) : | 16.46  |
|
| MACD | MACD : | -1.7 |
Signal : | -1.7 |
| %K %D | K(14,3) : | 25.3 |
D(3) : | 16.4 |
| RSI | RSI(14): 32.7 |
|||
| 52-week | High : | 25.77 | Low : | 4.59 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ GLUE ] has closed above bottom band by 13.3%. Bollinger Bands are 46.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 14.85 - 14.94 | 14.94 - 15.02 |
| Low: | 13.8 - 13.9 | 13.9 - 13.99 |
| Close: | 14.4 - 14.55 | 14.55 - 14.7 |
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
Wed, 26 Aug 2026
ADAR1 Capital Management LLC Buys Shares of 216,752 Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Tue, 25 Aug 2026
Monte Rosa Therapeutics (GLUE) Looks Pricey As Phase 2 Progress Keeps The Story Alive - simplywall.st
Tue, 25 Aug 2026
Monte Rosa Therapeutics (NASDAQ:GLUE) Trading 7.4% Higher on Analyst Upgrade - MarketBeat
Mon, 24 Aug 2026
Monte Rosa starts Phase 2 MRT-2359 prostate cancer trial - grafa.com
Mon, 24 Aug 2026
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 85 (M) |
| Shares Float | 54 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 115.7 (%) |
| Shares Short | 16,460 (K) |
| Shares Short P.Month | 18,630 (K) |
| EPS | -1.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.71 |
| Profit Margin | 0 % |
| Operating Margin | -547.9 % |
| Return on Assets (ttm) | -21.7 % |
| Return on Equity (ttm) | -42.7 % |
| Qtrly Rev. Growth | -61.3 % |
| Gross Profit (p.s.) | -1.57 |
| Sales Per Share | 0.33 |
| EBITDA (p.s.) | -2.04 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -24 (M) |
| Levered Free Cash Flow | -74 (M) |
| PE Ratio | -8.11 |
| PEG Ratio | 0 |
| Price to Book value | 2.48 |
| Price to Sales | 42.13 |
| Price to Cash Flow | -50.3 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|